JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, L.
Right arrow Articles by Enyeart, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, L.
Right arrow Articles by Enyeart, J. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 299, Issue 1, 227-237, October 2001

Neuroprotective Agent Riluzole Dramatically Slows Inactivation of Kv1.4 Potassium Channels by a Voltage-Dependent Oxidative Mechanism

Lin Xu, Judith A. Enyeart and John J. Enyeart

Department of Neuroscience, College of Medicine, The Ohio State University, Columbus, Ohio

The modulation of Kv1.4 K+ channels by the neuroprotective agent riluzole was studied in bovine adrenal zona fasciculata cells by using whole-cell patch clamp. At concentrations ranging from 1 to 100 µM, riluzole reversibly inhibited Kv1.4 channels (IC50 = 70 µM) and irreversibly slowed Kv1.4 inactivation. Riluzole (100 µM) increased the inactivation time constant (tau i) from a control value of 28.9 ± 3.9 to 623 ± 47.6 ms (n = 13). The slowing of bKv1.4 inactivation was not affected by substituting poorly hydrolyzable nucleotides for ATP in the pipette solution, or by the addition of cAMP. Riluzole-induced slowing of bKv1.4 inactivation was nearly eliminated by the presence of the antioxidant reduced glutathione (3 mM) or dithiothreitol (3-5 mM) in the recording pipette, or when cells were superfused with riluzole at a holding potential of -40 mV rather than -80 mV. These results are consistent with a model in which riluzole inhibits bKv1.4 currents and slows inactivation by separate mechanisms. Slowing of inactivation is independent of protein kinases, but probably involves oxidation of a cysteine in the N-terminal inactivation domain. Failure of riluzole to slow inactivation when applied to a depolarized cell suggests that this cysteine is protected in an inactivated Kv1.4 channel. The neuroprotective action of riluzole involves inhibition of glutamate release from presynaptic terminals within the central nervous system. Kv1.4 K+ channels are distributed throughout the brain in axons and nerve terminals, including those from which glutamate is released. The pronounced slowing of Kv1.4 inactivation by riluzole in these neurons could be an important mechanism underlying the inhibition of glutamate release and the therapeutic actions of this drug.


0022-3565/01/2991-0227$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
E. Idoux, D. Eugene, A. Chambaz, C. Magnani, J. A. White, and L. E. Moore
Control of Neuronal Persistent Activity by Voltage-Dependent Dendritic Properties
J Neurophysiol, September 1, 2008; 100(3): 1278 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
R. Balu and B. W. Strowbridge
Opposing Inward and Outward Conductances Regulate Rebound Discharges in Olfactory Mitral Cells
J Neurophysiol, March 1, 2007; 97(3): 1959 - 1968.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
E. V. S. Faustino and D. F. Donnelly
An important functional role of persistent Na+ current in carotid body hypoxia transduction
J Appl Physiol, October 1, 2006; 101(4): 1076 - 1084.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. S. Ahn, S. E. Kim, H.-J. Jang, M.-J. Kim, D.-J. Rhie, S.-H. Yoon, Y.-H. Jo, M.-S. Kim, K.-W. Sung, and S. J. Hahn
Interaction of Riluzole with the Closed Inactivated State of Kv4.3 Channels
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 323 - 331.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. Kanai, S. Kuwabara, S. Misawa, N. Tamura, K. Ogawara, M. Nakata, S. Sawai, T. Hattori, and H. Bostock
Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage
Brain, April 1, 2006; 129(4): 953 - 962.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Dunlop, H. Beal McIlvain, Y. She, and D. S. Howland
Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis
J. Neurosci., March 1, 2003; 23(5): 1688 - 1696.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.